Update on Salvage Options in Relapsed/Refractory Hodgkin Lymphoma after Autotransplant

Table 1

Selected clinical studies on treatment options in patients with relapsed/refractory Hodgkin’s lymphoma after autotransplant.

Author	Agent	Study design	Number of patients	Prior ASCT	Response	Median duration of response	Toxicity
Younes et al. [18]	Brentuximab vedotin	II	102	102; 70% PRD	ORR 75%; CR 34%; PR 40%	PFS 5.6 months; OS 22.4 months	PSN, fatigue, nausea, neutropenia, diarrhoea, and pyrexia
Younes et al. [22]	Rituximab	N/A	22	NR	ORR 22%; CR 1, PR 4	8.7 months	NR
Oki et al. [23]	Rituximab + gemcitabine	II	33	55%	ORR 48%; CR 5, PR 11	FFS 2.7 months	Gr 3-4 neutropenia and thrombocytopenia
O’Mahony et al. [24]	Daclizumab	II	30	NR	CR 12, PR 7, SD 5	N/A	Thrombocytopenia
Little et al. [25]	Vinblastine	N/A	17	17	ORR 59%; CR 12%; PR 47%	OS 38.8 months	Fever and neutropenia
Devizzi et al. [26]	Vinorelbine	N/A	24	NR	ORR 45%	N/A	N/A
Venkatesh et al. [27]	Gemcitabine	II	27	18	PR 22%; SD 52%	6.4 months	Gr 3 thrombocytopenia, neutropenia, and anemia
Spencer et al. [28]	Vinorelbine + gemcitabine	II	8	8	ORR 75%	N/A	N/A
Bartlett et al. [29]	Gemcitabine + vinorelbine + pegylated liposomal doxorubicin	II	91	40	ORR 75%; RR in prior ASCT; Pts 70%	8.5 months in; prior ASCT	Gr 3-4 thrombocytopenia neutropenia, and mucositis
de Filippi et al. [30]	Bendamustine	II	34	75%	ORR 56%; CR 33%; PR 19%	5 months	Gr 3-4 thrombocytopenia, anemia, and infections
Mendle et al. [34]	Bortezomib + gemcitabine	II	18	NR	ORR 22%	NR	Gr 3 elevation of transaminase enzyme
Kirschbaum et al. [35]	Vorinostat	II	25	NR	ORR 4%	PFS 4.8 months	Gr 4 anemia and lymphopenia; Gr 3 thrombocytopenia
Younes et al. [36]	Panobinostat	II	129	NR	DCR 74%; CR 5 PR 30	PFS 6.1 months	Gr 3-4 anemia, neutropenia, and thrombocytopenia
Johnston et al. [38]	Everolimus	II	19	84%	ORR 47%; CR 1 PR 8	TTP 7.2 months	Gr >3 pulmonary toxicity
Fehniger et al. [39]	Lenalidomide	II	36	87%	ORR 19%; CR 1 PR 6	NR	Gr 3-4 anemia and neutropenia thrombocytopenia
Georgakis et al. [40]	Tipifarnib	II	19	NR	ORR 21%; CR 2 PR 2	TTP 3.6 months; OR 14.8 months	Gr 3-4 anemia, neutropenia, thrombocytopenia, and fatigue

ASCT: autologous stem cell transplant; ORR: overall response rate; DCR: disease control rate; CR: complete response; PR: partial response; PFS: progression-free survival; FFS: failure-free survival; TTP: time to progression; Gr: grade; DOR: duration of response; NR: not reported.